Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
XmAb657 · 1 trial · 4 indications
| Arm | Type | Description |
|---|---|---|
| Dose Escalation | EXPERIMENTAL | XmAb657 administered SC |
| Name | Type | Description |
|---|---|---|
| XmAb657 | BIOLOGICAL | Biological |
Inclusion Criteria: Healthy participants - Adult participants in good health Idiopathic inflammatory myopathy (IIM) participants - Adult participants that meet the 2017 European Alliance of Association Rheumatology (EULAR)/American College of Rheumatology (ACR) Classification Criterion for IIM Sy...
XmAb657 is an investigational monoclonal antibody being developed for autoimmune diseases, including idiopathic inflammatory myopathies, systemic sclerosis, and Sjögren's disease. It is currently being studied in healthy participants as part of a Phase 1 clinical trial to evaluate its safety.
XmAb657 targets CD19, a protein found on the surface of B cells. By binding to CD19, the antibody is designed to modulate B-cell activity, which is relevant to autoimmune conditions where B cells contribute to disease pathology.
XmAb657 is being developed by Xencor, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol XNCR. The company is conducting a Phase 1 clinical trial to evaluate the drug's safety.
XmAb657 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The ongoing Phase 1 trial is recruiting participants to assess safety in healthy individuals and those with autoimmune diseases.
XmAb657 is being evaluated in a Phase 1 open-label trial with the identifier NCT07284797. This study is recruiting 60 participants in Australia to assess safety in healthy volunteers and individuals with autoimmune conditions, including idiopathic inflammatory myopathies, systemic sclerosis, and Sjögren's disease.